select

FREQUENTLY ASKED QUESTIONS

  • Why did the name change?

    • After receiving reports of dispensing errors due to the similarity between the names KAPIDEX (dexlansoprazole) and Casodex® (bicalutamide), and KAPIDEX and Kadian® (morphine sulfate extended-release), Takeda, in coordination with the US Food and Drug Administration, determined that a name change would be the best way to minimize future medication errors. At Takeda Pharmaceuticals, we believe patient safety is of the utmost importance.

      ONLY the name has changed. The size, strength, and ingredients of the capsule remain the same. Each capsule still contains 30 mg or 60 mg of dexlansoprazole.1 DEXILANT is still the first and only PPI with a Dual Delayed Release™ (DDR) formulation.1 The clinical relevance of this statement is unknown.

  • What are the patient’s eligibility requirements to use the DEXILANT Instant Savings Card?
    • The DEXILANT Instant Savings Card cannot be used if any part of the patient’s prescription is covered by: (i) any federal or state healthcare program (Medicare, Medicaid, VA, TriCARE, etc), including a state medical or pharmaceutical assistance program, (ii) the Medicare Prescription Drug Program (Part D), or if the patient is currently in the coverage gap, (iii) insurance that is paying the entire cost of the prescription, or (iv) an insurer or other Third Party Payor in Massachusetts.
  • What are the pharmacist’s requirements in submitting the DEXILANT Instant Savings Card for reimbursement?
    • By submitting a claim for reimbursement to PDMI, you certify that: (1) you have dispensed DEXILANT to an eligible patient in accordance with the eligibility requirements of this offer and the accompanying prescription; (2) you have not submitted and will not submit a claim for reimbursement for the portion of the drug covered by this offer to any Third Party Payor; and (3) your participation in this program is consistent with all applicable laws and any obligations, contractual or otherwise, that you may have as a pharmacy provider.

Reference: 1. DEXILANT (dexlansoprazole) package insert, Takeda Pharmaceuticals America, Inc.

DEXILANT is indicated for:

  • Healing all grades of erosive esophagitis (EE) for up to 8 weeks
  • Maintaining healing of EE and relief of heartburn for up to 6 months
  • Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for 4 weeks

Important Safety Information

  • DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported with DEXILANT use.
  • Symptomatic response with DEXILANT does not preclude the presence of gastric malignancy.
  • Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.
  • Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.
  • Most commonly reported adverse reactions were diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%).
  • Do not co-administer atazanavir with DEXILANT because atazanavir systemic concentrations may be substantially decreased. DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.

Please see the full Prescribing Information for DEXILANT.

This site is intended for US residents only